The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
暂无分享,去创建一个
A. Porcellini | D. Mercola | G. Giannini | L. Frati | A. Gulino | C. Liu | A. Arcella | A. Calogero | G. Ragona | V. Lombari | G. De Gregorio | R. Caruso | F. Gagliardi | M. Zani | G. Gregorio | Franco Maria Gagliardi | Giuseppe Ragona | Alberto Gulino | Giuseppe Giannini | Antonio Porcellini | Riccardo Caruso | Antonella Calogero | Dan Mercola | Chaoting Liu | Luigi Frati
[1] J. Milbrandt,et al. Ionizing Radiation Down-regulates p53 Protein in Primary Egr-1−/− Mouse Embryonic Fibroblast Cells Causing Enhanced Resistance to Apoptosis* , 2001, The Journal of Biological Chemistry.
[2] Erwin G. Van Meir,et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.
[3] C. Sherr. The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.
[4] D. Mercola,et al. The Transcription Factor EGR-1 Directly Transactivates the Fibronectin Gene and Enhances Attachment of Human Glioblastoma Cell Line U251* , 2000, The Journal of Biological Chemistry.
[5] A. López-Guillermo,et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. , 2000, The American journal of pathology.
[6] M. Roussel,et al. Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex , 2000, Molecular and Cellular Biology.
[7] N. Tsuchida,et al. The p16INK4alpha/p19ARF gene mutations are infrequent and are mutually exclusive to p53 mutations in Indian oral squamous cell carcinomas. , 2000, International Journal of Oncology.
[8] K. Ichimura,et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.
[9] D. Miller,et al. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. , 2000, Human pathology.
[10] M. Roussel,et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.
[11] A. Merlo,et al. Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.
[12] Ruo-Pan Huang,et al. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis , 1999, Oncogene.
[13] Ruo-Pan Huang,et al. The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor-β1, Fibronectin, and Plasminogen Activator Inhibitor-1* , 1999, The Journal of Biological Chemistry.
[14] M. During,et al. Towards gene therapy for the central nervous system. , 1998, Molecular medicine today.
[15] S. Rempel. Molecular biology of central nervous system tumors. , 1998, Current opinion in oncology.
[16] V. Rangnekar,et al. Suppression of growth and transformation and induction of apoptosis by EGR-1. , 1998, Cancer gene therapy.
[17] V. Rangnekar,et al. Ionizing Radiation-inducible Apoptosis in the Absence of p53 Linked to Transcription Factor EGR-1* , 1997, The Journal of Biological Chemistry.
[18] A. Beckmann,et al. Egr transcription factors in the nervous system , 1997, Neurochemistry International.
[19] A. Porcellini,et al. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells , 1997, Oncogene.
[20] V. Rangnekar,et al. Early Growth Response-1-dependent Apoptosis Is Mediated by p53* , 1997, The Journal of Biological Chemistry.
[21] D. Mercola,et al. Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation , 1997, International journal of cancer.
[22] D. Mercola,et al. Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines. , 1996, Oncogene.
[23] D. Mercola,et al. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Adamson,et al. UV activates growth factor receptors via reactive oxygen intermediates , 1996, The Journal of cell biology.
[25] S. Ménard,et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. , 1996, Cancer research.
[26] E. Ricevuto,et al. Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. , 1996, The American journal of pathology.
[27] Xiao-Fan Wang,et al. Functional Analysis of the Transforming Growth Factor βResponsive Elements in the WAF1/Cip1/p21 Promoter (*) , 1995, The Journal of Biological Chemistry.
[28] D. Mercola,et al. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. , 1995, Cancer research.
[29] V. Rangnekar,et al. Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6 , 1995, Molecular and cellular biology.
[30] R. Figlin,et al. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. , 1995, Oncogene.
[31] Xiao-Fan Wang,et al. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[32] G. Reifenberger,et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.
[33] D. Mercola,et al. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. , 1994, Oncogene.
[34] A. Levine,et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.
[35] F. Rauscher,et al. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[36] R. Espinosa,et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[37] G. Reifenberger,et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.
[38] M. Simmons,et al. Induction of Nitric Oxide Synthase in Glial Cells , 1992, Journal of neurochemistry.
[39] Eileen D. Adamson,et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization , 1988, Cell.
[40] J. Milbrandt,et al. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. , 1987, Science.
[41] C. Dani,et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. , 1985, Nucleic acids research.